Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome

IMPORTANCE: Mogamulizumab is a monoclonal antibody against CCR4 approved for treatment for mycosis fungoides (MF) and Sézary syndrome (SS). Mogamulizumab-associated rash (MAR) is difficult to differentiate from cutaneous MF or SS, which can lead to unnecessary discontinuation of drug use because of...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Dermatol
Main Authors: Hirotsu, Kelsey E., Neal, Tatiana M., Khodadoust, Michael S., Wang, Jennifer Y., Rieger, Kerri E., Strelo, Jenna, Hong, Eric, Kim, Youn H., Kwong, Bernice Y.
Format: Artigo
Language:Inglês
Published: American Medical Association 2021
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8060888/
https://ncbi.nlm.nih.gov/pubmed/33881447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2021.0877
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items